Prostate Cancer

While the risk of prostate cancer varies by family history, it is strongly associated with early onset of disease.

Ronald de Wit, MD, PhD, group leader, Experimental Systematic Therapy of Urogenital Cancers program, Erasmus MC Cancer Institute, Rotterdam, Netherlands, discusses the adverse events (AEs) with cabazitaxel (Jevtana) in the phase III CARD trial in patients with metastatic castration-resistant prostate cancer (mCRPC).

Maha Hussain, MD, FACP, FASCO, Genevieve E. Teuton Professor of Medicine in the Division of Hematology and Oncology, Department of Medicine, and Deputy Director at the Robert H. Lurie Comprehensive Cancer Center, of Northwestern University Feinberg School of Medicine, discusses the implications of the phase III PROfound trial in metastatic castration-resistant prostate cancer (mCRPC).

Chris Parker, MD, consultant clinical oncologist, The Royal Marsden NHS Foundation Trust, discusses the results of the phase III RADICALS-RT trial in prostate cancer.

Scott T. Tagawa, MD, MS, discusses remaining questions regarding treatment selection and PSMA imaging in metastatic castration-resistant prostate cancer.

Emmanuel S. Antonarakis, MBBCh, discusses the optimal use of PD-1/PD-L1 monotherapy in prostate cancer.

Stereotactic ablative radiation reduced disease progression compared with observation in patients with oligometastatic prostate cancer.

Rana R. McKay, MD, discusses the rationale for conducting a real-world analysis of radium-223 dichloride in metastatic castration-resistant prostate cancer.

Stephen J. Freedland, MD, discusses how real-world evidence with the use of enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) compares with data from the phase III PREVAIL trial.

Leonard G. Gomella, MD, discusses recommendations for screening in prostate cancer.

Scott T. Tagawa, MD, MS, discusses the safety profile of novel monoclonal antibody 225Ac-J591 in metastatic castration-resistant prostate cancer.

Petros Grivas, MD, PhD, discusses the role of targeted therapy in prostate cancer.

Moderate hypofractionated intensity-modulated radiation therapy did not show biochemical and/or clinical disease failure rate superiority compared with conventionally fractioned IMRT for men with intermediate- and high-risk prostate adenocarcinoma.

Wolfgang Fendler, MD, highlights the potential impact 68Ga-PSMA-11 PET imaging may have on the treatment of patients with biochemically recurrent prostate cancer.

Eugene B. Cone, MD, a urologic oncology fellow at Brigham and Women’s Hospital and Massachusetts General Hospital, discusses the methods that were used to evaluate the relative cardiac risk of gonadotropin-releasing hormone (GnRH) agonists versus antagonists in patients with prostate cancer.

Julie N. Graff, MD, associate professor of medicine, Oregon Health & Science University Knight Cancer Institute, discusses the phase III KEYNOTE-641 trial in metastatic castration-resistant prostate cancer (mCRPC).

Andrew J. Armstrong, MD, discusses the use of circulating tumor cell to detect chromosomal instability in men with metastatic castration-resistant prostate cancer.

Himisha Beltran, MD, discusses research evaluating cell-free DNA to identify therapy resistance in prostate cancer.

Anis Hamid, MBBS, discusses the hypothesis of predictive biomarkers for newly diagnosed metastatic hormone sensitive prostate cancer.

William K. Oh, MD, discusses sequencing challenges in prostate cancer, biomarker development, and the impact of the PRINT trial.

Andrew J. Armstrong, MD, discusses the utility of AR-V7 as a biomarker in prostate cancer.

Leonard G. Gomella, MD, professor, chair of the Department of Urology, and director of the Sidney Kimmel Cancer Center Network, of Thomas Jefferson University Hospital, discusses the evolution of androgen receptor (AR) inhibitors in prostate cancer.

Eugene B. Cone, MD, discusses the advantages of the study, the need for such research, and the potential to broaden these efforts to more novel agents such as abiraterone acetate, enzalutamide, and immune checkpoint inhibitors.